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(57) ABSTRACT 
Described herein is a multi-functional polymeric material 
for use in inhibiting adhesion and immune recognition 
between cells and cells, cells and tissues, and tissues and 
tissues. One component of the polymeric material adsorbs 
well to cells or tissue, and the other component of the 
polymeric material does not adsorb well to tissues. A water 
soluble polymer that does not bear charge (polynonion) is 
used as the non-binding component, and a water soluble 
polymer that is positively charged at physiological pH 
(polycation) is used as the tissue binding component. When 
the bi-functional polymeric material contacts a tissue, the 
tissue-binding component binds and thus immobilizes the 
attached non-binding component, which will then extend 
generally away from the tissue surface and sterically block 
the attachment of other tissues. The method and composi 
tions are useful in inhibiting formation of post-surgical 
adhesions, protecting damaged blood vessels from throm 
bosis and restenosis, and decreasing the extent of metastasis 
of attachment-dependent tumor cells. 
25 Claims, 2 Drawing Sheets 
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METHODS FOR MODIFYING CELL 
CONTACT WITH A SURFACE 
This is a divisional of prior application Ser. No. 08/132, 
507 filed on Oct. 5, 1993, by Jeffrey A. Hubbell, Donald 
Elbert, Jennifer L. Hill-West, Paul D. Drumheller, Sang 
hamitra Chowdhury, and Amarpreet Sawhney entitled "Mul 
tifunctional Organic Polymers,” and now U.S. Pat. No. 
5,462,990 which is a continuation-in-part of U.S. Ser. No. 
07/740,703 filed on Aug. 5, 1991, now U.S. Pat. No. 
5,380,536, which is a divisional of U.S. Ser. No. 07/598,880 
filed on Oct. 15, 1990, now abandoned. 
BACKGROUND OF THE INVENTION 
This invention is generally in the area of organic polymer 
chemistry, specifically multifunctional polymers. 
Cell adhesion plays an important role in human disease. 
These interactions proceed by the interaction of receptors 
upon the surface of a cell with proteins or glycosaminogly 
cans upon the surface of another cell or within the extra 
cellular matrix. These receptors may be proteins or gly 
cosaminoglycans. 
Routes to the interruption of these interactions typically 
involve competitive inhibition of these receptor-ligand inter 
actions, for example, with antibodies (e.g., anti-glycoprotein 
IIb/IIIa complex for anti-platelet therapy), soluble ligands 
which act as receptor antagonists (e.g., cyclic RGD peptides 
or von Willebrand factor fragments), soluble receptors, or 
other competitors. 
It has also recently been demonstrated that it is possible 
to inhibit these interactions by mechanical means, for 
example, by photopolymerizing poly(ethylene glycol)-based 
hydrogels upon the cell, cell aggregate, matrix or tissue. 
An example of the use of hydrogels to inhibit tissue 
adhesion is described by U.S. Pat. No. 5,126,141 to Henry. 
The process utilizes thermo-reversible gels of mixtures of 
polyoxyalkylene polymers and ionic polysaccharides 
applied to the tissues as liquids. 
Unfortunately, the inhibitor based methods have a disad 
vantage common to many drug therapies, in that it is difficult 
to restrict the activity of the inhibitors to the region of 
interest. Hydrogel barriers are difficult to place and it is 
difficult to control chemical processes associated with them. 
Isolated cells or tissues have also been protected from 
cell-cell contact, in this case from attack by immune cells, 
by placement within microcapsules formed of water soluble 
non-ionic polymers such as polyethylene oxide grafted to 
polycationic polymers such as poly-L-lysine. However, this 
is restricted to the use of isolated cells or tissues which are 
encapsulated within the polymer at the time of polymeriza 
tion for subsequent implantation into the body. 
It is therefore an object of the present invention to provide 
methods for making and using compositions, and the result 
ing compositions, for inhibiting tissue adhesion and cell 
cell contact within the body. 
It is a further object of the present invention to provide 
methods for making multifunctional polymeric materials 
which can be biodegradable and which can be used for drug 
delivery, either at a specific tissue-polymeric material inter 
face or as a result of release of bioactive agents during 
degradation of polymeric material. 
SUMMARY OF THE INVENTION 
A bi-functional polymeric material for use in inhibiting 














one domain of the material (i.e., one region with a particular 
function) is a polymer which adsorbs to cells or tissue 
(referred to collectively below as “tissue'), and the other 
domain of the polymeric material is a polymer which does 
not adsorb to tissue. Since most tissues bear a net negative 
charge, a positively charged polymer (polycation) is used as 
the tissue-binding domain. A water-soluble polymer that 
does not bear charge (polynonion) is used as the non-binding 
domain. When the two-domain polymeric material contacts 
a tissue, the tissue-binding domain(s) binds and immobilizes 
the attached non-binding domain(s), which then generally 
extends away from the tissue surface and sterically blocks 
the attachment of other tissues. 
Additional domains, linking groups, and bioactive mate 
rials can be added to this basic two-domain structure to 
confer, for example, adhesion to particular types of cells or 
molecules or degradation by enzymatic or non-enzymatic 
means. These domains may be a third type of polymer, or 
when serving to direct attachment, a peptide such as RGD, 
or even a single amino acid, which is used to target a 
polyamino acid for cleavage by an enzyme. 
The polymer is applied in a fluid phase to the tissues or 
cells to be protected, whereupon the tissue binding domains 
adsorb the polymeric material to the tissue. The fluid phase 
can be applied to isolated tissue or to tissue during surgery 
or by means of a catheter or other less invasive device. 
The compositions are useful for blocking adhesion and 
immune recognition and thus may be useful in the treatment 
of many diseases, including the prevention of postoperative 
adhesions, protecting injured blood vessels from thrombosis 
and intimal thickening relating to restenosis, and decreasing 
the extent of metastasis of tumor cells in tissues. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic illustration of the interaction 
between a two domain polymeric material and cells or tissue 
which has been treated with the polymeric material to 
decrease adhesiveness. 
FIGS. 2a and 2b are photographs of a rat carotid artery 24 
hours after crush injury without treatment (FIG. 2a) and 
treated with a 5% solution of PEG-b-PLL for two minutes 
(FIG. 2b). 
DETAILED DESCRIPTION OF THE 
INVENTION 
I. General Structures of the Polymers 
There are three general structures of the polymeric mate 
rials described herein. Each structure is a block copolymer, 
i.e., a polymer composed of connecting multiple polymer 
chains of different composition. The three structures are (1) 
brush copolymers (as in a bottle brush, with a backbone of 
one composition and bristles of another) with a backbone of 
poly(B) and bristles composed of poly(A), (A)x-b-(B)y; (2) 
AB block copolymers, i.e., (A)x(B)y, or a poly(A) connected 
at one end to a poly (B); and (3) ABA block copolymers, i.e., 
(A)x(B)y(A)Z, or a poly(A) connected at both ends to 
poly(A) chains, or in a less preferred embodiment, 
(B)x(A)y(B)Z; where A is a monomer, the polymer of which 
does not bind strongly to a tissue; B is a monomer, the 
polymer of which does bind strongly to a tissue; x is an 
integer of greater than or equal to 5; y is an integer of greater 
than or equal to 3; and Z is an integer greater than or equal 
to zero. As used herein, "polymeric materials' include 
polymers of oligomers. X is determined as that number 
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providing the desired degree of repulsiveness or non-adhe 
Siveness to tissue; y is determined as that number providing 
the desired degree of adhesiveness of the polymeric material 
to tissues, as discussed in more detail below. Poly(A) and 
poly(B) are generally linear polymers, although both may be 
linear or branched. Both A and B can be monomers, mac 
romers or polymers. 
A. Selection of "(B) n' 
"(B)n” can be any biocompatible water-soluble polyca 
tionic polymer, for example, any polymer having protonated 
heterocycles attached as pendant groups. As used herein, 
"water soluble” means that the entire polymer, poly(B)y, 
must be soluble in aqueous solutions, such as buffered saline 
or buffered saline with small amounts of added organic 
solvents as cosolvents, at a temperature between 20° and 37 
C. In some embodiments, poly(B) will not be sufficiently 
Soluble in aqueous solutions per se but can be brought into 
solution by grafting with water-soluble poly(A) chains. 
Examples include polyamines having amine groups on 
either the polymer backbone or the polymer sidechains, such 
as poly-L-lysine and other positively charged polyamino 
acids of natural or synthetic amino acids or mixtures of 
amino acids, including poly(D-lysine), poly(ornithine), pol 
y(arginine), and poly(histidine), and nonpeptide polyamines 
such as poly(aminostyrene), poly(aminoacrylate), poly 
(N-methyl aminoacrylate), poly (N-ethylaminoacrylate), 
poly(N,N-dimethyl aminoacrylate), poly(N,N-diethylami 
noacrylate), poly(aminomethacrylate), poly(N-methyl 
amino-methacrylate), poly(N-ethyl aminomethacrylate), 
poly(N,N-dimethyl aminomethacrylate), poly(N,N-diethyl 
aminomethacrylate), poly(ethyleneimine), polymers of qua 
ternary amines, such as poly(N.N.N-trimethylaminoacrylate 
chloride), poly(methyacrylamidopropyltrimethyl ammo 
nium chloride), and natural or synthetic polysaccharides 
Such as chitosan. 
B. Selection of “(A)n' 
Any biocompatible, preferably polynonionic at a pH of 
between 6.5 and 8.5, polymer that does not bind to tissue can 
be used as (A)x. These include poly(oxyalkylene oxides) 
such as poly(ethylene oxide), poly(ethyloxazoline), poly(N- 
vinyl pyrrolidone), poly(vinyl alcohol), and neutral 
poly(amino acids) such as poly(serine), poly(threonine), and 
poly(glutamine) and copolymers of the monomers thereof, 
polysaccharides such as dextran, water soluble cellulose 
derivatives such as hydroxy ethyl cellulose, poly(hydroxy 
ethyl acrylate), poly(hydroxy ethylmethacrylate) and poly 
acrylamide. 
In Some cases, polymers that bear a net negative charge 
(polyanion) will also function well as the non-binding 
domain, but only in cases where the interaction between the 
polycation and the polyanion is such that the two-domain 
polymer does not precipitate due to the interactions between 
the opposite charges. When polyanionic polymers are mixed 
with polycationic polymers, the mixture often precipitates 
due to the interaction of the opposite charges on the two 
polymers. The extent to which this occurs depends upon the 
nature of the charges of the particular polymers in question, 
as well as their solvent environment. Such precipitation may 
also occur with the block copolymers, if polyanions are used 
as the (A)x domains. There may, however, be polyanion 
(A)x and polycation (B)y combinations that will not pre 
cipitate, which may be determined experimentally by those 














weak acids such as polyalcohols may be expected to behave 
in this way. Polyalcohols are such weak acids that they may 
be considered for the purposes described herein as being 
essentially polynonionic. Negatively charged polymers from 
polyacids may also be determined to form stable, soluble 
copolymers with suitable polycations in useful aqueous 
formulations. 
It should also be understood that the (A)x and the (B)y 
blocks could themselves be copolymeric, so long as they 
retain their dominant polynonionic (for (A)x) or polyca 
tionic (for (B)y) character. For example, an (A)x could 
consist of a copolymer of ethylene oxide and another 
water-soluble, nonionic comonomer, and a (B)y could con 
sist of a copolymer of lysine and another amino acid with a 
cationic (e.g., arginine) or nonionic (e.g., glycine) side 
chain. 
An example of a preferred polymeric material as 
described herein is formed of poly(L-lysine) (abbreviated 
PLL), "(B)y', and poly(ethylene oxide), also known as 
poly(ethylene glycol) or poly(oxyethylene) (abbreviated 
PEG), “(A)x'. The end groups on the PEG should not be 
considered as specified by the name PEG. 
Block copolymers of PLL and PEG are useful two 
domain polymeric materials, where the PEG domain, which 
does not bind well to tissues, is immobilized upon a tissue 
by the adsorption of the PLL, which does bind well to the 
1SSle. 
In general, the molecular weight of (B)y must be sufficient 
to yield the desired degree of binding, generally including at 
least five charges, and having a molecular weight of at least 
300 g/mole. In general, the molecular weight of (A)x must 
be sufficient to provide the desired degree of repellency of 
tissue or macromolecules, taking into consideration poten 
tial steric hindrance of the polymer, generally requiring a 
molecular weight of at least 300 g/mole. The lengths of the 
(A)x and the (B)y in the domains which would result in good 
blockage of adhesive and immune interactions may be 
determined by routine experimentation. In general, the 
larger the ratio of (A)x mass to (B)y mass, the weaker the 
binding of the polymer and the stronger the repulsion of 
potentially attaching tissues would be. Thus, the function of 
the polymer is used to determine an optimum amount of 
(B)x required to yield good binding and the optimum 
amount of (A)y to yield good repulsion. It should be 
understood that "good” is a word that must be defined by the 
requirements of the particular circumstance at hand, e.g., 
how long binding is required and how complete a repulsion 
is required by the particular medical application. In addition 
to the mass ratio of (A)x to (B)y, the number of chains of 
(A)x and the number of chains of (B)y may be varied from 
many A:B to 1 A:B in (A)x-b-(B) y; to 2 A:B in 
(A)x(B)y(A)z; to 1 A:B in (A)x(B)y), as can the absolute 
lengths of the two chains (e.g., an (A)x-b-(B)y with a 
particular mass fraction of A:B with many short (B)y may 
function in a different manner than one with a few long (B)y 
chains). 
II. Specialized Structures of the Polymers 
Modifications of the bi-functional polymers are shown 
diagrammatically below. The first functionality is the char 
acteristic of tissue adsorbancy, determined by (B)y. The 
second functionality is the characteristic of not adsorbing to 
tissue, or tissue repellency, determined by (A)x. 
5,567,440 
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A A A 
BBBBBBBBBBB AAABBBBBBBBAAA AAABBBB 
(Brush Block (ABA Block (AB Block 
Copolymer) Copolymer) Copolymer) 
wherein: 
A denotes a domain that does not adsorb well to tissues; 
and 
B denotes a domain that adsorbs well to tissues, such as 
the polycation poly-L-lysine (PLL). 
When present on the tissues, the two-domain polymers 
will adsorb to the tissues in a conformation that could be 
graphically represented as follows, where the solid line 
represents the tissue surface: 
A. A. A A A A 
A A A A A A 
A A. A A A A 
BBBBBBBBBBB BBBBBBBB BBBB 
(Brush Block (ABA Block (AB Block 
Copolymer) Copolymer) Copolymer) 
As shown above, the B component adsorbs well to the 
tissue, and the A component, which has no strong interaction 
with the tissue, dangles generally away from it. The net 
effect of the adsorption of the dual function polymeric 
material is to link to tissue the A component, which by itself 
does not bind well to tissues, thus blocking the adhesion of 
other cells, tissues, or macromolecules to the treated surface. 
Although described herein with reference to (A)x con 
sisting of a single polymer, the structures shown diagram 
matically above can be synthesized using mixtures of poly 
mers as (A)x. For example, the "bristles' on the brush 
polymers could be formed of different (A)x, (A)x, (A)x, 
(A)x, etc., as could the termini on the AGA block copoly 
mers. These embodiments consisting of one or more types of 
polymers (A)x are referred to jointly herein as (A)x. 
ABA block copolymers are expected to be more effective 
in repelling tissues than BAB block copolymers, i.e., with a 
central nonbinding block and peripheral binding blocks. 
However, there may be cases where BAB block copolymers 
demonstrate high binding to the tissues and high degrees of 
repulsion of approaching tissues. This is especially true with 
the use of strongly binding, short (B)y regions with a long 
central (A)x region. 
A. Control of Duration of Binding 
It may be desirable to control the duration of the repul 
siveness of the polymeric material or the duration of the 
presence of the polymeric material. There are several ways 
in which this can be accomplished. These are generally 
divided into (1) selection of (B)y on the basis of the strength, 
or lack of strength, of binding over time to tissue; (2) 
modification of the polymeric material to incorporate a 
domain C resulting in degradation of the polymeric material 
and/or separation of the binding component (B)y from the 
repulsive component (A)x; and synthesis of polymeric mate 
rial where either the binding component (B)y is converted 
into a non-binding component (D)y or the repulsive com 
ponent (A)x is converted into a non-repulsive or binding 
component (F)y. 
1. Selection of Type and Relative Ratios of Binding 
and Repulsive Components 
In the first case, it may be desirable to control the duration 














controlling its rate of desorption. Such control may be 
desirable to control the duration of repulsiveness or to 
control its presence for regulatory or toxicological concerns. 
Control can be achieved in several ways. Various (B)y 
would be expected to bind to the tissue with different 
strength. For example, a poly(L-histidine) would be 
expected to bind to tissues less strongly than a poly(L- 
arginine) of the same chain length (i.e., same y in (B)y), 
because a lower fraction of the histidine residues are charged 
at physiologic pH than of the arginine residues. The stronger 
the binding of the (B)y, the longer the duration of binding 
would be. The strength of binding of various (A)x-b-(B)y, 
(A)x(B)y, and (A)x(B)y(A)z will depend upon the particular 
structure of the polymer and upon the ratio of mass of (A)x 
to (B)y. In either of these cases, the duration of binding is 
determined by the rate of desorption without any chemical 
changes in the polymer. 
2. Incorporation of Degradable Regions or 
Cleavage Sites into the Polymers 
A component which is subject to degradation can be 
selected to control the duration of the presence of or the 
repulsion of the polymer. This can be accomplished by 
selecting an (B)y that is degraded by nonenzymatic hydroly 
sis, such as a polyester, polyamide, polyurethane, or poly 
anhydride; or that is degraded by enzymatic hydrolysis, such 
as a polypeptide or polysaccharide. Oxidative mechanisms 
may also be utilized to achieve degradation. For example, 
ether, urethane, and tertiary carbon structures are known to 
be sensitive to oxidative degradation. The use of these 
structures in the copolymer may lead to degradation by 
reactions, e.g., nitric oxide, peroxynitrite, or hypochlorite. 
Homopolymeric backbones or regions (B)y are expected to 
have differential stability to nonenzymatic or enzymatic 
degradation in vivo, e.g., poly-L-lysine, poly-D-lysine, 
polyornithine, polyhistadine, and polyarginine should dis 
play differential stability. For example, poly(D-lysine) 
would be expected to be more resistant proteolytic degra 
dation than poly(L-lysine). 
The polymeric material can be targeted for cleavage by an 
enzyme by including a recognition amino acid or recogni 
tion sequence for an enzyme within the polymeric material. 
This targeting component is referred to herein as 'C'. In 
general, the enzyme will be a naturally occurring protease 
such as trypsin, thrombin, factor XII, factor XIII, other 
coagulation factors, collagenase, elastase, plasmin, or other 
endoprotease or ectoprotease which recognize specific 
amino acid sequences. Individual amino acids can be incor 
porated into the polymer to make the polymer sensitive to 
degradation by less specific proteases. Saccharide or oli 
gosaccharide regions which are cleaved by a variety of 
enzymes present in tissues, such as amylases, could also be 
used. 
Component C could also be selected to be sensitive to 
nonenzymatic hydrolysis, for example, a dimer of lactic 
acid, the ester of which is sensitive to hydrolysis. In this way, 
the non-binding (A)x is cleaved from the (B)y, separating 
the polymeric material into its two components, one of 
which no longer binds and the other which no longer repels 
tissue. Other nonenzymatically sensitive sites could also be 
selected, such as other esters, amides, anhydrides, and 
numerous others apparent to those skilled in the art of 
degradable polymers. 
Considerable tailoring of this loss of repulsiveness may be 
obtained by controlling how the repulsive bristles fall off via 
the cleavage or degradation of component C. This degrada 
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tion may be controlled by the action of water without any 
enzymatic activity, and thus would be solely a function of 
time, or by the action of an enzyme. Two types of enzyme 
sensitivities could be selected: a sequence that is sensitive to 
a constitutively expressed enzyme, e.g., coagulation factor 
Xa, so that degradation would still be mostly a function of 
time, or one could select a sequence that is sensitive to a 
regulated enzyme, such as plasmin or collagenase, both of 
which are expressed at the leading edge of many types of 
migrating cells during healing. This would allow a cell, 10 
during healing, to wipe away the repulsiveness that was 
protecting the surface prior to healing. 
In terms of timing the duration of the presence of the 
material, degradation of the adsorbing region B would result 
in removal of the polymeric material from the surface of the 15 
tissue. This may be important from the perspectives of both 
optimal efficacy and regulatory approval, where the mini 
mum residence of the polymeric material in the body is 
desired. 
Different embodiments of these modifications can be 
designed, for example, the (A)x can be connected to the (B)y 
via a linker C, to form (A)xC-b-(B)y, (A)xC(B)y, or 
(A)xC(B)yC(A)Z. These embodiments are shown schemati 
cally below. 
At longer times: 
20 
8 
the backbone of the polymer may be selected to undergo a 
nondegradative chemical transformation to alter its affinity 
for the tissue. 
In one embodiment, one can obtain desorption by con 
verting the (B)y region to a nonadsorbing region, (D)y, 
either by the action of water or through the use of a 
constitutive or regulated enzyme. For example, poly(L- 
glutamic acid) could be selected as a backbone. This poly 
mer does not bind well to tissues since it is polyanionic. It 
can be converted to a tissue-binding polymer by esterifica 
tion with a compound such as bromoethylamine hydrochlo 
ride, or by amidification with a compound such as ethylene 
diamine. The esters and amides are hydrolytically sensitive 
and will, with time, be converted back to poly(L-glutamic 
acid) and ethanolamine or ethylene diamine, with the poly(L 
glutamic acid) region readily desorbing. For example, the 
side chain carboxyls are esterified with ethanolamine (amine 
protected), so that subsequent hydrolysis of the ester in vivo 
releases the (binding, B) amine to produce a (non-binding, 
D) carboxyl. Alternatively, the side chain carboxyls may be 
amidated with ethylenedianime (one amine protected), and 
subsequent hydrolysis of the amide in vivo releases the 
(binding, B) amine to produce a (nonbinding, D) carboxyl. 
This embodiment is shown diagrammatically below: 
A. A. A A A A 
A A A -\ A A A or A A. A 
A A A -/ A A A A A A 
C C C A. A. A C C C 
BBBBBBBBBBB 
BBBBBBBBBBB BBBBBBBBBBB 
(Brush Block Copolymer) (C degrades and agent 
with Degradation-labile diffuses away; long B 
Bristles) segments remain) 
At longer times 
A. A A. A. A A A A 
A A A-\ A A A or A A. A 
A A A -/ A A A A A A 
BBCBBCBBCB BB BB BB B BBC BBC BBC B 
(Brush Block Copolymer) (C degrades and agent 
with Degradation-labile diffuses away; 
Backbone short B segments desorb) 
wherein 
C denotes a cleavage site, for example, for cleavage via 
enzymatic or nonenzymatic hydrolysis. 50 
3. Selection of (A)x or (B)y which is Converted 
into Domains Having Different Binding Affinities 
The duration of binding may also be controlled by design 
ing chemical sensitivities into the polymers. For example, 
At short times At longer times At even longer 
times 
A A A A. A. A A A A 
A A A - G A A A - G A A A 
A. A. A A. A. A A. A. A 
BBBBBBBBBBB BDBDBBDBBDD DDDDDDDDDDD 
(Brush Block (B, which binds, (Polymer 
Copolymer with converting to D, desorbs) 
Reactively 
labile Backbone) 




D denotes a nonbinding group which arises by reaction of 
B, a binding group. B converts into D after binding. 
In another embodiment, one can design nonadhesive 
components (A)x that react in vivo to yield domains con 
sisting of (E)x that are no longer repulsive. For example, a 
polyamine could be selected as the adhesive component. The 
amine groups could be protected by reaction with a car 
boxyl-containing group, such as a (hydroxyl protected) 
hydroxy acid (with subsequent deprotection). The resulting 
amide bond would render the original amine much less 
adhesive and more repulsive, yielding the A)x component. 
Over time, hydrolysis of the amide bond would result in loss 
of the hydroxy acid, forming the original amine, which 
would increase adhesiveness and decline in repulsiveness. 
Such chemical conversions in vivo could occur nonenzy 
matically, as described above, or enzymatically, either by a 
constitutively present or regulated enzyme, as described 
further above. 
This is described diagrammatically below. 
At even 
longer times 
At short times At longer times 
A A A 
A A A 
A A A 
BBBBBBBBBBBB 
A A E 
E. A. E 






(A, which repels, 
converting to E, 






E denotes an adhesive group, which arose by reaction of 
A, a repulsive group. 
In summary, the overall adsorption of the polymer to a 
tissue, and then its repulsion of other tissues, is an optimi 
zation: with much (B)y, adsorption will be strong, but 
subsequent repulsion will be weak; and with much (A)x, 
repulsion will be strong, but adsorption will be weak. 
There are at least two general ways to determine the 
duration of repulsiveness: (1) by timing the duration of the 
presence of the polymeric material on the tissue surface, 
e.g., by timing degradation of the backbone, reaction of (A)x 
or (B)y to result in desorption, or desorption without deg 
radation by varying binding affinity of (B)y; and (2) by 
timing the duration of the repulsiveness of the polymeric 
material on the surface, e.g., by timing the degradation of the 
repulsive components (A)x or reaction of (A)x to result in 
loss of repulsion. 
B. Attachment of Bioactive Species 
Additional activities may be added to the polymeric 
material by attaching bioactive species ("F) to the ends of 
the (A)x, elsewhere on the (A)x, or onto the (B)y. Such 
bioactive species may be adhesion peptides, adhesion oli 
gosaccharides, antibodies, enzymes, receptor ligands, or 
drugs. Bioactive species may be used to target adhesion of 
the polymeric material, to effect a biological activity at the 
polymeric material-tissue interface, or to effect an activity 
when released during degradation of the polymeric material. 
For example, the adhesion peptide Tyr-Ile-Gly-Ser-Arg, 
from laminin, binds to receptors on endothelial cells, but not 
on blood platelets. Thus, the addition of the oligopeptide 
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the polymeric material to a damaged vessel wall would be 
expected to block thrombosis on the vessel wall but not to 
block reendothelialization from the surrounding undamaged 
vessel wall. This embodiment makes it possible to cover the 
thrombogenicity of an injured vessel wall but, via an adhe 
sion ligand F on the termini of the (A)x components, to 
permit the regrowth of endothelial cells upon the polymer. In 
this case, F is the pentapeptide Tyr-Ile-Gly-Ser-Arg 
(YIGSR), which supports endothelial, smooth muscle cell, 
and fibroblast adhesion, but not platelet adhesion; or the 
tetrapeptide Arg-Glu-Asp-Val (REDV), which has been 
shown to support endothelial cell adhesion but not that of 
smooth muscle cells, fibroblasts, or platelets, J. A. Hubbell, 
et al., "Endothelial cell-selective materials for tissue engi 
neering in the vascular graft via a new receptor BioTech 
nology 9:568-572 (1991), the teachings of which are incor 
porated herein. This approach also permits the 
reendothelialization of the vessel wall while it is still not 
adhesive to platelets, thus enabling healing while avoiding 
platelet activation and thrombus formation. 
In another embodiment, an enzyme F is coupled to the 
(A)x termini, thereby covering up the platelet reactivity of 
the damaged vessel (in angioplasty injury) or mesothelium 
(in pelvic adhesions) while at the same time immobilizing a 
beneficial biological activity. Examples of useful enzymes 
include tissue plasminogen activator (tPA), since plasmino 
gen activation is desirable in both prevention of pelvic/ 
abdominal adhesions and in the resorption of vascular 
thrombus. Numerous other bioactive species may be ben 
eficial. 
This embodiment is shown schematically as: 
F F F 
A A. A 
A. A. A 
A A. A 
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(Brush Block Copolymer 




III. Synthesis of Polymers 
In general, methods for synthesis of the different poly 
meric materials will be apparent to those skilled in the art 
from the foregoing description. 
A. Brush Block Copolymers 
1. Method for Grafting A upon the e Amines of B, 
with all the e Amines Deprotected, Using 
Stoichiometric Control in Water 
PEG may be bonded to the e-amines of lysine residues of 
poly(L-lysine) as follows. Poly(L-lysine) (PLL) is reacted 
5,567,440 
11 
with monomethoxy PEG, the terminal hydroxyl of which 
has been previously activated with carbonyldiimidizole 
(CDI). The PLL and the activated PEG are mixed in an 
aqueous solution buffered at pH 9 and allowed to react for 
48 hours at room temperature. The number of PEG chains 
grafted per PLL chain may be controlled by the ratio of 
moles activated PEG added per mole PLL added. The 
reaction may not proceed to completion, i.e., the mole ratio 
of PEG to PLL in the reaction mixture may not be identical 
to that in the PEG-b-PLL product, but higher ratios of PEG 
to PLL will produce higher amounts of PEG in the PEG-b- 
PLL product. 
2. Method for Grafting A onto the e Amines of B, 
with all the e Amines Deprotected. Using 
Stoichiometric Control in Anhydrous Solvent 
The cationic domains tend to be highly reactive, and 
efforts must be made to control the extent of addition of 'A' 
to "B". Executing the reaction in the absence of water 
reduces deactivation of 'A' and allows better stoichiometric 
control. For example, unprotected poly-L-lysine is dissolved 
in water, then added to dimethylformamide (DMF) to make 
a solution that is 5% aqueous. The poly-L-lysine is then 
reacted with CDI mono-activated PEG in stoichiometric 
amounts, followed by evaporation of solvent under vacuum 
yielding an (A)x-b-(B)y copolymer. Alternatively, unpro 
tected poly-L-lysine is dissolved in water and is precipitated 
by addition of NaOH. The precipitated polymer is added to 
anhydrous DMF and then reacted with CDI mono-activated 
PEG in stoichiometric amounts, yielding an (A)x-b-(B)y 
copolymer. When the reaction is performed in the absence of 
water, side reactions involving the activated group are 
reduced (i.e., deactivation is reduced), and at long reaction 
times the ratio of mole PLL to PEG in the polymer product 
more closely resembles than in the reactant mixture. 
3. Grafting A upon the e Amines of B, with a 
Controlled Number of Those Amines Deprotected 
Solution polymerization of PLL may be carried out using 
monomers containing different epsilon protecting groups, 
which allows strict control over the degree of substitution of 
“A” onto "B". N-carboxyanhydrides of various amino acids 
may be synthesized and polymerized into copolymers, as in 
the following example. N,N'-dicarbobenzoxy-L-lysine (Z.Z- 
lysine) is reacted with phosphorus pentachloride to yield 
e.N-carbobenzoxy-o,N-carboxy-L-lysine anhydride. O.N- 
carbobenzoxy-e,N-tert-butyloxycarbonyl-L-lysine (Z,boc 
lysine) is reacted with sodium methoxide to yield the sodium 
salt of Z,boc-lysine. The sodium salt of Zboc-lysine is 
reacted with phosphorus pentachloride to yield e,N-tert 
butyloxycarbonyl-O.N-carboxy-L-lysine anhydride. Z.Z- 
lysine anhydride is added to Zboc-lysine anhydride, and the 
two monomers are polymerized by the addition of sodium 
methoxide as an initiator. A copolymer results, poly(e boc 
lysine)-co-(e. Z-lysine). The boc groups are removed by 
addition of the polymer to trifluoroacetic acid for fifteen 
minutes. The salt form is converted to the free base by 
reaction with a reactant such as pyridine. The free amines on 
the polymer are then reacted with CDI PEG in DMF. The Z 
groups are deprotected by addition of the polymer to HBr in 
acetic acid for fifteen minutes, yielding an (A)x-b-(B)y 
copolymer, where the ratio of PEG to PLL in the final 
product is controlled by the inital ratio of boc protected 
lysines, which were ultimately grafted with PEG, to Z. 















As an alternative to solution polymerization, greater con 
trol over the length of the “B” segment may be obtained 
through the use of solid phase orthogonal synthesis. For 
example, poly-L-lysine is synthesized using a peptide syn 
thesizer. The monomer lysines used in the synthesis are of 
two types. One type of lysine is O-amine protected using the 
F-moc protecting group (9-fluorenylmethyloxycarbonyl 
group), and is e-amine protected with the Z protecting group 
(benzyloxycarbonyl group). The second type of lysine is 
O-amine protected using the F-moc protecting group, and is 
e-amine protected with the t-Boc protecting group (tert. 
butyloxycarbonyl group). A thirty residue peptide is con 
structed, with one t-boc protected lysine per nine Z protected 
lysines. The t-boc groups are selectively cleaved by immer 
sion of the peptide in neat trifluoroacetic acid for fifteen 
minutes, and then desalted with pyridine. The free amines 
are reacted with CDI mono-activated PEG in DMF. The Z 
groups are then deprotected with HBr in acetic acid for 15 
minutes, yielding an (A)X-b-(B)y copolymer. 
4. Solid Phase Synthesis of PLL Copolymerized 
with Another Residue, the Side Groups of which 
are Used for Grafting of A 
Not only may the protecting groups be varied, but the type 
of residue may also be changed. For example, on a peptide 
synthesizer, a peptide is made utilizing both Z. protected 
lysine and tert. butyl protected aspartic acid in a ratio of nine 
lysines per one aspartic acid. The tert. butyl group is 
deprotected by immersion of the polymer in neat trifluoro 
acetic acid. The free carboxyl groups are activated with 
O-(N-Succinimidyl)-N,N,N',N'-tetramethyluronium tet 
rafluoroborate (TSU) in DMF. The TSU activated peptide is 
reacted with mono-amine-PEG in DMF. The Z protecting 
groups on the lysines are removed by incubation of the 
peptide with HBr in acetic acid, yielding an (A)x-b-(B)y 
copolymer. 
B. AB (and ABA) Block Copolymers 
1. Grafting A to the Terminal Amine (and 
Carboxyl) Prior to Deprotection of the e Amines 
It may be desirable to produce versions of the polymer 
which are not of a brush structure. This may be facilitated by 
not deprotecting the epsilon amines of PLL, so that the only 
reactive groups are the amine and carboxyl termini. For 
example, reaction of CDI mon-activated PEG with poly 
e.N-carbobenzoxy-L-lysine in DMF yields an (A)x-(B)y 
copolymer. Activation of the carboxyl terminus of the (A)x- 
(B)y copolymer with TSU followed by reaction with mono 
amino PEG in DMF yields an (A)x-(B)y-(A)z copolymer. 
2. Solid Phase Synthesis of PLL Using Two 
Monomer Lysines with Different Amine Protection 
Chemistries, the N (and C) Terminal Residue(s) 
Being Differently Protected than the Other Lysine 
Residues 
The presence of a free amine on both ends of the “B” 
segment would require fewer reactions to attach "A" seg 
ments to the ends of the polymer. This may be done by 
beginning the synthesis with a residue containing an epsilon 
protecting group which may be removed without disturbing 
the other epsilon protecting groups. The "A" chain reacts 
with this free amine, as well as the free amine at the N 
terminus of the peptide. For example, poly e.N-carboben 
Zoxy-L-lysine is synthesized by solid phase methods, and 
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the e-residue at the carboxyl terminus is boc protected, with 
all other e-residues Z protected. The boc is removed in 
trifluoroacetic acid, and the free amines are reacted with CDI 
mono-activated PEG in DMF. The Z groups are removed 
with HBr in acetic acid, yielding an (A)x-(B)y-(A)Z copoly 
c. 
3. Solid Phase Synthesis of PLL Copolymerized 
With Another Residue, the N (and C) Terminal 
Residues Being the Different Composition, the Side 
Group(s) of which will be Used for Grafting of A 
Beginning the synthesis of a pure poly-L-arginine chain 
with a lysine will place a reactive amine at both ends of the 
poly-L-arginine chain. The poly-L-arginine would be the 
"B' binding segment, and 'A' segments could be placed 
onto the amines. For example, poly-L-arginine is synthe 
sized by solid phase methods, but the residue at the carboxyl 
terminus is aboc protected lysine. The boc group is removed 
in trifluoroacetic acid, and the peptide is reacted with CDI 
PEG in pH 9 buffered water, yielding an (A)x-(B)y-(A)z 
copolymer, with the (B)y segment representing poly-L- 
arginine. 
The following examples are exemplary of methods of 
synthesis for the specialized modified embodiments of the 
polymeric materials. 
4. Solution Phase Polymerization of N-carboxyl 
Anhydride Lysine with PEG as Initiator to Yield 
AB Copolymer 
In the solution phase polymerization of a polyamino acid, 
the sodium salt of the PEG may be used as an initiator. For 
example, the polymerization of the N-carboxy anhydride of 
lysine is initiated by the sodium salt of monomethoxy PEG, 
as described by Pratten, M. K., Lloyd, J. B., Horpel, G., 
Ringsdorf, H., "Micelle-forming block copolymers: Pinocy 
tosis by macrophages and interaction with model mem 
branes', Makromol. Chem. 186, 725-33 (1985). 
5. Polymerization of Ethylene Oxide with PLL as 
Initiator 
Ethylene oxide is polymerized to PEG by the addition of 
an initiator, with incorporation of the initiator into the 
polymer. For example: Ethylene oxide polymerization is 
initiated by the addition of poly e.N-carbobenzoxy-L-lysine, 
which leads to PEG-copoly e,N-carbobenzoxy-L-lysine. 
C. Incorporation of a Degradative or Cleavage 
Component, C, into the Polymer 
The time of residence of the polymer on the tissue and the 
ability of the host to clear the polymer may be enhanced by 
incorporating sequences which are non-enzymatically 
degradable. 
1. For Degradation at Bristles by Addition of a C 
Component 
C can be added to the polymeric material so that the 
"bristles' are released from the backbone when the C 
component degrades. For example, monomethoxy PEG 
reacts with d,l-lactide (1:3 molar ratio) in xylene in the 















yield a PEG with an end group which degrades over time in 
water. The hydroxyl at the terminus of the trilactide end 
group is activated with CDI, which is then further reacted 
with PLL by methods presented above to yield an (A)xC 
b-(B)y, an (A)xC-(B)y or an (A)xC-(B)y-C(A)Z copolymer. 
2. Incorporation of C into the Backbone for 
Enzymatic Degradation of the Backbone 
Certain amino acid sequences are recognized by specific 
proteolytic enzymes. These may be incorporated into a 
polyloeptide backbone. For example, by solid phase meth 
ods, a peptide is produced which contains six lysines, 
followed by the sequence proline-X-glycine-proline, where 
X is any neutral amino acid, and repeated three times to 
obtain a peptide with 30 residues. The sequence proline-X- 
glycine-proline is hydrolysed by the enzyme collagenase. 
The peptide is reacted with CDI mono-activated PEG to 
yield an (A)x-b-C(B)y, an (A)x-C(B)y or an (A)x-C(B)yC 
(A)Z copolymer which is enzymatically degradable. 
D. Synthesis of a Polymeric Material Using a 
Component that Changes From One Function to a 
Second Function Over Time 
1. Synthesis of a Polymeric Material Using a B 
Component that Converts from a Binding 
Component to a Non-binding Component D 
The duration of binding of a polymeric material can be 
controlled by synthesis of a polymeric material with a 
non-binding backbone which is converted to a binding 
backbone through degradable linkages. For example, termi 
nal amine polyglutamic acid is reacted with CDI PEG to 
produce an (A)x(D)y-b-(B)y copolymer. The copolymer is 
dissolved in water at pH 2 and lyophilized to convert the 
carboxylic acid salt to the free acid. The polymer is dis 
solved in DMF, and the glutamic acid residues are activated 
with TSU. The activated polymer is then reacted with boc 
protected aminoethanol in DMF overnight at room tempera 
ture and then deprotected and desalted. The product is 
initially polycationic and binding, but hydrolyses to a non 
binding polyanion. 
2. Synthesis of a Polymeric Material Using an A 
Component that Converts from Repelling Tissue to 
One which does not Repel or Bind to Tissue 
A polypeptide may be reacted with an (unprotected) 
hydroxy acid using peptide synthesis techniques to yield a 
nonionic polymer. Over time, this amide linkage degrades, 
and the nonion converts from repulsive to not repulsive. For 
example, using solid phase synthesis, a peptide is produced 
in which the first twenty residues are lysines, the next ten 
residues are arginine, and the next twenty residues are 
lysines. The peptide is fully deprotected, and is then reacted 
with lactic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodi 
imide (EDC), and N-hydroxysulfosuccinimide in buffered 
water at pH 9, yielding an (A)x-(B)y-(A)Z copolymer in 
which the “A” segment is originally nonionic, but upon 
degradation becomes ionic. 
E. Addition of Bioactive Components to the 
Polymeric Material 
Some interactions of tissues with the polymer may be 
desirable. A variety of mechanisms can be used to effect this 
result, including cell specific peptide sequences that can be 
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used to target the polymer to bind only to certain cell types, 
or to attract or inhibit binding of soluble mediators, includ 
ing enzymes. 
1. Incorporation of Cell Specific Peptide Sequences 
Cell specific peptide sequences can be incorporated into 
the copolymer as follows. The peptide tyrosine-isoleucine 
glycine-serine-arginine (YIGSR) is fully protected with the 
exception of the carboxyl terminus, and is activated with 
2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU). This is then reacted with 
mono-amino PEG in DMF, giving O-hydroxy, co-YIGSR 
PEG. This compound is CDI activated in DMF, reacted with 
PLL in DMF, followed by deprotection of YIGSR in DMF, 
yielding a copolymer with a pendant bioactive agent. 
2. Derivatization of PEG with an Amino Acid 
The derivitization of PEG with an amino acid makes it 
suitable for inclusion into a polypeptide using solid phase 
techniques. For example, CDI mono-activated PEG is 
reacted with O-Fmoc protected lysine, forming e-lysine 
PEG. Using solid phase techniques, a copolymer is made of 
lysines and e-lysine-PEGs, using the method of Atassi, M. 
Z., Manshouri, T., "Synthesis of Tolerogenic Monomethoxy 
polyethylene Glycol and Polyvinyl Alcohol Conjugates of 
Peptides' J. Prot. Chem., 10, 623-1 (1991), the teachings of 
which are incorporated herein. 
III. Medical Applications of Polymers 
As described above, the bi-functional polymers have a 
variety of applications. Several are demonstrated in detail in 
the following examples. These include local application, 
either at the time of surgery or via injection into tissue, to 
prevent adhesion of tissues; to deliver bioactive compounds 
where release is effected more efficiently or at a more 
desirable rate or where tissue encapsulation could detrimen 
tally effect or delay release; prevention of thrombus forma 
tion at blood vessel surfaces, particularly following angio 
plasty; alteration of attachment of cells, especially to prevent 
attachment of cells, and therefore decrease metastasis of 
tumor cells; and as coatings on prosthetic implants such as 
heart valves and vascular grafts derived from processed 
tSSueS. 
As defined herein, “tissue' includes cells, cell aggregates, 
tissues removed from the body, and tissues present in the 
body. This term can also be applied to treated tissue, such as 
tissue heart valves, blood vessels and membranes, where the 
tissue is no longer living and has been chemically fixed, or 
a cryopreserved blood vessel or other tissue. 
The polymeric materials can be applied directly by local 
ized or topical application, or if targeted as described herein, 
systemically. Topical or localized application is achieved 
generally by spraying or injecting a very thin layer (usually 
on the order of monolayers of polymeric material) onto the 
tissue surface to which adhesion is desired. Methods for 
applying the polymeric materials in this manner are known 
to those skilled in the art. 
As described below in the examples, these polymeric 
materials have been applied in three systems where the 
prevention of cell and tissue contact is desirable. 
1. Damage to the surface of organs during surgery may 
cause adherence of tissues which are in close contact. This 
problem is particularly severe in reproductive surgery, where 














surgical model in rats, an injury was made to the uterine 
horns, followed by treatment with PEG-b-PLL. Adhesions 
were reduced from an extent of 78% for control (treated with 
HEPES-buffered saline, the vehicle) to 9% for treatment 
with a 1% concentration of the polymeric material by 
peritoneal lavage. 
2. After balloon angioplasty, damage to the endothelium 
may lead to thrombus formation, due to the interaction of 
platelets with the vessel wall. Moreover, thrombosis may 
lead to restenosis. In rats, an injury was made to the carotid 
artery, followed by treatment with PEG-b-PLL. Thrombosis 
was completely blocked by exposure to a 5% concentration 
of the polymeric material prior to resumption of blood 
COntact. 
3. During laparoscopic removal of tumors, tumor cells 
may be released into the pelvic cavity, and the tumor cells 
may metastasize. Tumor cells were incubated with PEG-b- 
PLL, and then seeded intraperitoneally in mice. Implantation 
of tumor cells upon the injured tissue surfaces was reduced 
from 0.93 g in controls to 0.17 g in treated animals. 
There are a number of other medical applications for the 
polymeric materials described herein. 
1. Thrombosis upon injured vascular surfaces may cause 
complications in vascular surgery. This is especially true in 
microvascular surgery, where thrombosis at the ends of the 
vessels at the anastomosis may lead to occlusion. Prior to 
anastomosis, the ends of the vessels to be joined are dipped 
in a 1% solution of PLL-b-PEG, or a similar bi-functional 
polymeric material, to pacify the injured vessel surfaces. 
Thrombosis may thus be reduced, and vessel patency may be 
improved. 
2. Cardiovascular implants are adversely affected by 
thrombosis, platelet attachment and aggregation. As an 
example, thrombosis upon the surfaces of heart valve 
implants made from human or animal tissues processed, for 
example, by cryopreservation, lyophilization or chemical 
fixation, is implicated in acting as a nidus for calcification. 
Thus, thrombosis may lead to long-term valve failure by 
calcification of the valve to materials. Tissue heart valves are 
placed in a 2% solution of PEG-b-PLL, or a similar bifunc 
tional polymeric material, in buffered saline at 4 C. for 1 
hour. The valve is then rinsed in saline for 5 minutes and 
packaged for implantation later. During the incubation in the 
polymeric material solution, the bi-functional polymeric 
material adsorbs by its binding domain, thus immobilizing 
the non-binding domain in the processed tissue valve. This 
subsequently blocks thrombosis after implantation, and 
long-term calcification at the sites of thrombosis may thus be 
reduced. 
3. The adhesion of immune cells to the vascular surface of 
a transplanted organ is one of the causes of acute organ 
rejection. This acute rejection may be related to an acute 
inflammatory reaction, in which white blood cells adhere to 
the vascular surface of the transplanted organ. Hearts for 
transplantation are placed in a preservation medium con 
taining added bi-domain polymeric material, such as PEG 
b-PLL. The organ is stored in the medium, e.g., at 4 C., 
until transplantation. During the storage period, the bifunc 
tional polymeric material adsorbs to the vascular surface of 
the organ, which subsequently blocks the adhesion of 
immune cells to the organ after transplantation. This may 
reduce acute rejection of the organ. 
4. In many cases, it may be advantageous to have a drug 
that is immobilized upon and or released from a surface. An 
example is the fibrinolytic enzyme streptokinase (SK). 
Streptokinase is considered inferior to tissue plasminogen 
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activator (tPA) because tRA binds to fibrin and exerts its 
fibrinolytic activity in an immobilized manner. SK exhibits 
no such binding. This difficulty can be eliminated by binding 
of the enzyme to the polymeric material described herein. 
SK is attached to the ends of the non-binding domains which 
are connected to a binding domain. In this case, since the 
bioactive group is rather large, being an enzyme, a fewer 
number of nonbinding domains is optimal, as is a larger 
binding domain. The SK-grafted bi-domain polymeric mate 
rial, e.g., SK-grafted PEG-PLL AB block copolymer, is 
administered locally to the site of balloon angioplasty using 
a catheter, such as a balloon catheter that weeps fluid. The 
SK-PEG-PLL binds to the vessel surface, yielding a local 
ized and more sustained fibrinolytic activity exactly at the 
site of its application. 
The same technology can be applied using any of numer 
ous other classes of drugs, such as growth factors, growth 
factor antagonists, receptor antagonists, adhesion factors, 
adhesion antagonists, antimitotics, antisense oligonucle 
otides, and many others. In a similar approach, the drug is 
attached to the ends of the nonbinding domain via a cleav 
able linker, such as a lactic acid dimer or oligomer, or an 
enzymatically cleavable peptide or saccharide. In this way, 
a controlled release of the tissue-bound drug may be engi 
neered into the conjugate of the drug with the bi-functional 
polymer. 
5. In vascular injury, such as occurs when a diseased 
coronary artery is injured by balloon angioplasty, the endot 
helial monolayer that protects the vessel wall from contact 
with blood is removed. Thrombosis follows due to blodd 
platelet binding to proteins in the injured vessel wall. This 
interaction can be blocked using bi-functional polymeric 
materials, such as poly(N-vinyl pyrrolidinone)-chitosan 
block copolymers, abbreviated PVP-chitosan. The ratio of 
the PVP to chitosan, and the molecular configuration of the 
PVP-chitosan, which is dependent on the number of PVP per 
chitosan, may be optimized to resist substantially all adhe 
sion of blood cells to the vessel wall. This blocks thrombo 
sis, which is suspected to cause further vessel disease such 
as restenosis. It may also slow the process of reendothelial 
ization. A bioadhesive domain may be attached to the ends 
of the nonbinding domains, and this bioadhesive domain 
may be selected to bind to endothelial cells and support their 
adhesion but not to blood platelets so as to support throm 
bosis. The laminin pentapeptide tyr-ile-gly-ser-arg (YIGSR) 
is attached via its N-terminal primary amine to end-groups 
on the PVP-chitosan AB block copolymer. After adsorption, 
the nonbinding groups block thrombosis, but the YIGSR 
peptide on the termini of the nonbinding groups support the 
attachment and migration of endothelial cells from the 
noninjured periphery of the blood vessel. This may thus 
accelerate vascular healing and permit reendothelialization 
of the injured Zone without contact of the artery with blood. 
Such approaches may be carried out on numerous other 
tissues, e.g., a demesothelialized surface to accelerate peri 
toneal healing and prevent adhesions, and a deepithelialized 
cornea to accelerate healing after corneal abrasion, among 
others. 
6. In some cases the binding domain may be highly 
specific in nature, rather than nonspecific as with exclusively 
polycationic binding domains. For example, a water-soluble 
polymer that is nonionic, such as poly(vinyl alcohol) (PVA), 
may be grafted to a receptor antagonist, such as a receptor 
antagonist that binds to adhesion receptors on cell surfaces. 
For example, a PEG-PVA AB block copolymer is synthe 
sized. Subsequently, several sialyl Lewis-X (LeX) oligosac 














chain. This PEG-Lex-PVA copolymer is administered by 
injection into the blood stream. The polymeric material 
binds to the surfaces of cells expressing E-selectin, which 
binds to LeX. Since there are several LeX oligosaccharides 
bound to the PVA domain, binding to E-selectin on cell 
surfaces is quite strong. Thus, the LeX PVA domain serves 
as the binding domain, and the PEG domain serves as the 
nonbinding domain. The net effect may thus be to block the 
adhesion of cells via numerous receptors by immobilizing a 
nonbinding domain such as PEG to the surface of the cell. 
IV. Optimization of the Polymeric Material for 
Individual Applications 
The biological performance of these materials is opti 
mized by altering the structure of the polymers, the ratio of 
the number of tissue-binding polymers to non-binding poly 
mers, and the ratio of the mass of the tissue-binding poly 
mers to non-binding polymers. 
In some case, polymeric materials exhibiting more than 
one manner of degradation may be required to achieve 
different results. For example, degradation by nonenzymatic 
hydrolysis will depend primarily upon the accessibility of 
the polymeric material to water and the local pH. Given that 
pH and water concentration are similar throughout many 
parts of the body, such a mode of degradation would yield 
a loss in repulsiveness that depends mostly upon time. As 
another example, if the degradable region was sensitive to an 
enzyme, the activity of which was not highly regulated but 
rather was present in the body fluids at a more or less 
constant level, the rate of loss of repulsiveness would again 
depend primarily upon time. As another example, if the 
degradable region was sensitive to an enzyme, the activity of 
which was more highly regulated, the rate of loss of repul 
siveness would then depend more upon the expression of 
that particular enzyme activity. For example, many types of 
cells express the proteases plasmin or collagenase during 
migration. A sensitivity to plasmin would then cause all 
migrating cells to degrade the repulsiveness of the polymeric 
material and thus attach. This might be useful, e.g., in 
protecting an injured vessel wall from blood platelets, but 
permitting an endothelial cell migrating from a noninjured 
region of the vessel wall to migrate over the treated area, 
degrading its nonadhesiveness as it did so and permitting the 
endothelial cell to attach to the vessel wall and migrate over 
it. This could permit reendothelialization of a de-endothe 
lialized vessel wall without ever permitting direct contact of 
the endothelial cell-free surface with blood platelets. 
The biological performance of these polymeric materials 
depends upon their structure. Specific features of biological 
performance include binding to the tissue, repulsion of 
opposing tissues, duration of binding to the tissue, duration 
of repulsion of opposing tissues, and the mode of loss of 
binding or repulsion. Specific features of polymeric material 
structure include the type (chemical composition) of tissue 
binding domain, type of non-binding domain, the ratio of the 
mass of binding to non-binding domains, the number of 
binding to non-binding domains, the inclusion of sites that 
are particularly susceptible to nonenzymatic hydrolysis, the 
inclusion of sites that are particularly susceptible to enzy 
matic hydrolysis, and the inclusions of sites with particular 
biological affinity. 
A variety of ways can be utilized to optimize the desired 
properties. For example, when a PEG-b-PLL brush copoly 
mer is used to protect an injured tissue surface from the 
adhesion of cells approaching from the fluid phase in contact 
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with that tissue surface, the polymeric material can be made 
more desirable by studies conducted using a tissue culture 
model, such as cell adhesion to gelatin coated surfaces in 
tissue culture medium containing 20% serum. Gelatin is 
coated upon the multiwell dishes using standard tissue 
culture technique, for example, from a 3% gelatin solution. 
A 30 minute exposure to medium with 20% serum will lead 
to the adsorption of fibronectin, a protein leading to cell 
adhesion, to the gelatin surface. If fibroblasts are seeded on 
this surface in medium containing 20% serum, rapid adhe 
sion and spreading will occur. A measurement of the fraction 
of cells adhering (Fa) and fraction of cells spreading (Fs) 
may be made based on morphological criteria using light 
microscopy. Such measurements conducted 4 hours follow 
ing Seeding provide useful measures of adhesion and repul 
sion. A family of PEG-b-PLL polymeric materials are syn 
thesized, e.g., according to the following schedule: 
Fraction of lysine residues 
MW of PLL MW of PEG grafted with a PEG chain 
1000 1000 1150 
1000 1000 1110 
1000 1000 115 
10000 1000 1150 
10000 000 1f10 
0000 1000 115 
10000 5000 1150 
10000 5000 110 
10000 5000 115 
OOOO 10000 1150 
10000 10000 1f10 
10000 10000 115 
20000 5000 150 
10000 5000 1110 
20000 5000 f5 
20000 10000 1150 
20000 10000 1110 
20000 10000 15 
For each polymeric material composition, Fa and Fb are 
measured at 4 hours. Polymeric materials with very low ratio 
of PEG to PLL, such as the polymeric material with 20000 
Da PLL, 5000 Da PEG, with /$0 of the lysine residues 
grafted with a PEG chain, would be expected to be relatively 
ineffective in prevention of fibroblast attachment and 
spreading. 
In the case where a brush copolymer which desorbs 
slowly from tissue is desirable, the same assay system could 
be used, and polymeric materials could be synthesized with 
other binding domains, such as in the schedule below: 
Fraction of 
MW of binding residues 
Binding domain binding grafted with a 
composition domain MW of PEG PEG chain 
Poly Llysine 20000 Da 50000 Da 1110 
Poly L histidine 20000 5000 10 
Poly Larginine 20000 5000 110 
Poly L 20000 5000 1110 
ornithine 
Poly 20000 5000 1110 
ethyleneimine 
Poly amino 20000 5000 1110 
ethylacrylate 
Chitosan 20000 5000 1110 
By varying the specific nature of the charge, in this 
example used to obtain binding to tissues, the rate of 
desorption may be adjusted. In the assay system, cells could 
be seeded once each day on a gelatin surface variously 














Afterwards, the substrates could be rinsed with medium and 
stored in tissue culture with medium for examination after 
the next day. Subsequent measurements over many weeks 
would permit the rate of loss of cell repulsiveness to be 
determined for each formulation. 
In the situation where an AB block copolymer was to be 
used to prevent thrombosis and intimal thickening upon an 
artery surface injured by balloon angioplasty, after initial 
experimentation as described above to determine a desirable 
ratio of binding domain to non-binding domain, and a 
desirable optimal composition of the binding and non 
binding domains, animal experimentation could be per 
formed. For example, if the above experimentation yielded 
good repulsion for 14 days with PLL of degree of polymer 
ization (DP) 30 and a PEG of DP 150, animal experimen 
tation could be performed making small excursions about 











Thrombosis could be measured at 24 hours following 
injury and treatment, and intimal thickening could be mea 
Sured at 28 days following injury and treatment, using light 
microscopy with histological staining with Gomori's 
trichrome staining for the measurement of thrombosis and 
Verhoeff's staining for the measurement of intimal thicken 
1ng. 
If it were desired to further optimize, for example based 
on the nature of the binding domain, an optimal formulation 
from the above schedule could be selected, and the PLL 
domain could be replaced with poly(L-histidine), poly(L- 
arginine), poly(L-ornithine), polyethyleneimine, poly(ami 
noethylacrylate), and chitosan, with guidance from the 
experimentation in vitro. 
If it were desired to further optimize based on the rate of 
degradation of the binding domain, an optimal formulation 
from the above schedule could be selected and the poly(L- 
amino acid) binding domain could be replaced with a 
poly(D-amino acid) domain of the same amino acid, for 
example poly(D-lysine) for poly(L-lysine). Each polyamino 
acid would be expected to exhibit different stability to 
proteolysis in vivo. - 
If it were desired to even further optimize based on the 
rate of degradation of the binding domain, an optimal 
formulation from the above schedule could be selected and 
a protease sensitive site could be placed between the binding 
and the non-binding domains. For example, many cells 
express proteases on their leading edge as they migrate, such 
as plasmin, collagenase, or elastase. By appropriate selec 
tion of a protease sensitive site it should be possible to 
design a polymeric material that is sensitive to endothelial 
migration, permitting the polymeric material to prevent 
thrombosis, but also permitting the polymeric material to be 
degraded by endothelial cells repopulating the vessel surface 
as healing and reendothelialization occurs. 
A similar outcome may be obtained by placing adhesion 
peptides at the termini of the non-binding domains. For 
example, the laminin peptide tyr-ile-gly-ser-arg is known to 
support endothelial cell adhesion and spreading. However, 
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platelets do not bind avidly to this sequence. It is thus 
possible to synthesize an AB block copolymer with the 
adhesion peptide on the termini, or elsewhere, on the non 
binding domain. This may also permit the prevention of 
platelet contact while at the same time permitting endothe 
lial cells to migrate over the injured vessel Zone to repopu 
late and reendothelialize the injured zone. 
An AB block copolymer can be used to immobilize a drug 
upon a tissue surface. For example, the formation of fibrin 
is known to be involved in the formation of postoperative 
adhesions, and fibrinolytic proteins have been shown to be 
effective in reducing adhesion formation. More expensive 
fibrinolytic proteins such as tissue plasminogen activator 
(tPA) have advantages over less expensive ones such as 
streptokinase (SK) in that the tRA binds to the tissue surface 
at sites of fibrin. This retention of tRA by immobilization is 
an important benefit. This retention may be mimicked, 
however, by attaching the SK to a bi-domain polymeric 
material. For example, a family of AB block copolymer 
could be synthesized according to the following schedule: 
DP of PLL DP of PEG Presence of SK 
25 100 Yes 
50 100 Yes 
100 100 Yes 
25 500 Yes 
50 500 Yes 
100 500 Yes 
These polymeric materials could be evaluated for the 
ability to prevent postoperative adhesion in rats after devas 
cularization injury of the uterine horn, each delivered as a 
1% solution in buffered saline. After selection of an optimal 
formation, the equivalent polymeric material could be syn 
thesized with albumin, an inactive protein, rather than SK to 
serve as a control. 
The present invention will be further understood by 
reference to the following non-limiting examples. 
EXAMPLE 1. 
Synthesis and Characterization of PEG-b-PLL 
Materials and Methods 
PEG-b-PLL Synthesis 
Poly(ethylene glycol) was grafted to poly(L-lysine) based 
on the calculations of Sawhney and Hubbell, "Poly(ethylene 
oxide)-graft-poly(L-lysine) copolymers to enhance the bio 
compatibility of poly(L-lysine)alginate microcapsule men 
branes' Biomaterials 13:863–870 (1992), and on the chem 
istry of Beauchamp, et al., "A new procedure for the 
synthesis of polyethylene glycol-protein aducts: the effects 
on function, receptor recognition, and clearance of super 
oxide dismutase, lactoferrin, and alpha 2 macroglobulin' 
Anal. Biochem. 131:25-33 (1983), the teachings of which 
are incorporated herein. Monomethoxy terminated poly(eth 
ylene glycol(PEG) (20 g, mol. wt. 5000; Aldrich, Milwau 
kee, Wis., USA) was dried by azeotropic distillation from 
benzene, and precipitated by addition to anhydrous diethyl 
ether. The polymer was dried overnight under vacuum, and 
stored under argon. The terminal hydroxyl on the PEG was 
then activated with 1,1-carbonyldiimidazole (CDI; Sigma, 
St. Louis, Mo.). Under argon, CDI (0.194 g) was weighed 
out, then added to dry PEG (10 g) in anhydrous dichlo 














temperature for two hours, and the product was then pre 
cipitated by addition to anhydrous ether. The product was 
dried under vacuum overnight. 
Poly(L-lysine) (PLL) (1 g, mol. wt. 21,400; Sigma) was 
dissolved in 25 ml of 50 mM sodium borate buffer (pH 9) 
and filter sterilized three times through 0.2 um syringe filters 
(Nalgene, Rochester, N.Y.) to remove microbial contamina 
tion. In a sterile reaction bulb and in a sterile cabinet, CDI 
activated PEG (CDI-PEG) (6.6 g) was added to the poly(L- 
lysine) solution with vigorous stirring for one day. The 
solution was then dialyzed (SpectraPortM dialysis tubing, 
MW cutoff 12,000-14,000; Spectrum Medical Industries, 
Los Angeles, Calif.) against four liters of phosphate buffered 
saline (pH 7.4) for one day. The solution was then freeze 
dried, yielding 3.44 g of product. 
NMR Analysis of PEG-b-PLL 
H NMR analysis of PEG-b-PLL was performed in DO 
on a 500 MHz. General Electric instrument. 
Results 
H NMR analysis of PEG-b-PLL in DO indicated the 
presence of new peaks which were not present in the 
individual spectra of PLL or PEO. These peaks corre 
sponded to the conversion of some epsilon amines on the 
PLL. The new peaks were presumably due to the addition of 
PEG to the PLL. Analysis of the peak at 2.9 ppm, corre 
sponding to the protons on the delta carbon on the PLL side 
chain, and a smaller peak at 3.0 ppm, corresponding to the 
protons on delta carbons of side chains which had reacted 
with CDI-PEG, indicated that 5.73% of the lysyl residues 
had reacted with CDI-PEG. This corresponds to 9.57 PEG 
chains per PLL chain, or an average molecular weight of 
PEG-b-PLL of 69,250 Daltons. Comparison of the peaks at 
2.9 ppm and 3.0 ppm with the peak at 3.3 ppm, resulting 
from the monomethoxy group on the PEG, indicated that 
only 19.3% of the PEG in the product was actually attached 
to the PLL. This was due to incomplete dialysis of the 
product, however, the presence of the PEG could be 
accounted for in the experiments by the choice of appropri 
ate controls. 
EXAMPLE 2 
Effect of PEG-b-PLL on Cell Spreading 
Monomethoxy PEG off on One Capped End in 
Vitro 
Materials and Methods 
Human foreskin fibroblasts (HFFs) were incubated in 
DMEM containing 10% fetal bovine serum (FBS) with 
0.2% PEG-b-PLL (as described in Example 1), PLL or PEG 
for five minutes, and were then seeded into 24 well dishes 
which also contained DMEM with 10% FBS and 0.2% (w/v) 
of the appropriate polymer. The fibroblasts were seeded at 
2000, 10,000, 25,000 or 40,000 cells/cm, with two repli 
cates at each concentration. At three hours post seeding, the 
number of well spread cells and the number of total cells was 
counted at 200x on a Nikon phase contrast inverted micro 
scope, two fields per well, and the percentage of cells which 




The percentage of spread cells (spread cells/total cellsX 
100) is an indication of seeding efficiency. Seeding effi 
ciency will remain relatively constant regardless of concen 
tration of cells within the range of cell concentrations 
studied here However, a polymer which prevents spreading 
at low concentrations may be ineffective at higher concen 
trations. Thus, it is logical to examine a range of cell seeding 
concentrations. 
TABLE 1. 
Prevention of Fibroblast Spreading 
concentration of cells (cells/cm 
2000 10,000 25,000 40,000 
polymer % spread cells, std. dev. 
control 50.8 - 18.4 37.5 + .71 39.5 + 9.19 59.0 it 5.66 
MPEG 33.8 - 26.9 56.0 - 14 59.5 - 12.0 62.5.71 
PLL 5.75 - 7.22 23.57.78 27.5 - 3.54 410 - 141 
PEG-b-PLL 0.000 1.0 E 141 0.571 1571 
PLL seems to inhibit spreading somewhat of HFF's at low 
cell concentrations, however, at higher seeding concentra 
tions, PLL allowed cell spreading. PEG-b-PLL strongly 
inhibited fibroblast spreading at all concentrations tested. 
EXAMPLE 3 
In Vivo Study of the Use of PEG-b-PLL to Prevent 
Pelvic Adhesions 
Materials and Methods 
PEG-b-PLL (as described in Example 1) was tested at a 
1% concentration in 10 mM HEPES buffered saline. From 
gravimetric analysis, it was estimated that PEG-b-PLL was 
20% PLL by weight. Thus, 0.2% PLL and 0.8% PEG were 
mixed together in 10 mM HEPES buffered saline as a 
control, referred to as the PLL+PEG control. To control for 
the individual effects of PLL and PEG, a 0.2% solution of 
PLL, referred to as the PLL control, and a 0.8% solution of 
PEG, referred to as the PEG control, were prepared, both in 
10 mM HEPES buffered Saline. HEPES buffered Saline 
alone was also tested, referred to as the HEPES control. 
The polymer solutions were prepared as follows: The 10 
mM HEPES buffered saline was first autoclaved and then 
filter sterilized (150 ml disposable filter system, Corning, 
Corning, N.Y.) before addition to polymers. Polymer solu 
tions were shaken until dissolved, and then syringe filter 
sterilized as above. The solutions containing PLL, however, 
were filter sterilized four times to assure removal of micro 
bial contamination. The polymer solutions looked identical, 
and were labeled by a code to assure that the surgeries would 
be performed blind. 
Controlled injuries to the uterine horn in 14 week old rats 
were made by electrocautery to devascularize the horns and 
produce serosal injury on the antimesenteric surfaces. Seven 
days after Surgery, the animals were sacrificed and the horns 
were examined. The portion of the horn which was judged 
to be adhered to mesentery or rectum was measured with a 
ruler, and compared to the total length of the horn. This 
"percent adhesion” refers to the length of the horn which 
displayed adhesions compared to the total length of the horn. 















between the two horns. This average value was considered 
to be one data point. 
The uterine horns were judged to be free of adhesions 
(grade 0), containing filmy adhesions (grade 1) or containing 
severe adhesions (grade 2). If only a portion of an adhesion 
was found to be grade 2, the length of the grade 2 area was 
measured, and compared to the length of the adhesion which 
was grade 1. It was thus possible to score a horn with an 
intermediary value between grade 1 and grade 2. The grade 
of adhesions in the animals were averaged between the two 
horns. 
Data for percent adhesion of horn was analyzed using a 
one factor analysis of variance. Data for severity of adhe 
sions was analyzed using the distribution free, non-paramet 
ric Kruskal-Wallis test. 
Results 
The extent of adhesions as assessed seven days after 
uterine horn injury is presented in Table 2. 
TABLE 2 
Extent of Adhesions 
Treatment ave. 76 adhesion Std. Dev. Count 
HEPES 77.9 6.62 7 
MPEG 344 3.77 6 
PLL 26.0 4.76 7 
PEG -- PLL 20.3 8.10 7 
PEG-b-PLL 8.79 4.09 7 
All treatments differ significantly from other treatments at 
95% by the Fisher PLSD post-hoc test, except for PLL 
versus PEG-PLL, which did not differ significantly. 
The extent of adhesions was reduced by the application of 
PEG, PLL or PEG-b-PLL as compared to the HEPES alone 
control. The combination of PEG plus PLL did not differ 
significantly from PLL alone. The PEG-b-PLL treatment 
was significantly different from the PEG-PLL treatment. 
The severity of adhesions was also assessed and is pre 
sented in Table 3. The data gathered concerning the grade of 
the adhesions was parametric, but not normally distributed. 
The average grade was calculated, and is indicative of the 
severity of the adhesions. The standard deviation is useful to 
judge the reproducibility of the data, despite the lack of 
statistical meaning due to the non-normal distribution. The 
data was analyzed using a rank sum type test. The ranksum 
from each treatment was divided by the number of samples 
in the treatment, yielding the mean rank. 
TABLE 3 
Severity of Adhesions 
Treatment ave. grade std. dev. mean rank 
HEPES 157 45 26.7 
PEG 1.08 20 17.0 
PLL 1.03 07 16.1 
PLL - PEG 107 19 6.6 
PEG-b-PLL 821 3. 10.9 
The Kruskal-Wallis test suggested a statistical difference 





In Vivo Study: Prevention of Thrombosis 
Following Artery Crush Using PEG-b-PLL 
Materials and Methods 
Malc Sprague-Dawley rats weighing 350–400 g were 
used in this study. The animals were anaesthetized with 
pentobarbital (50 mg/kg body weight). Xylocaine was 
administered subcutaneously in the region of the Surgical 
manipulations just prior to incision. The carotid artery was 
exposed by careful dissection 1 cm. beyond the external 
carotid branch point. Atraumatic arterial clips were used to 
clamp off the artery at the most proximal exposed point of 
the internal and external carotid branches and at the most 
distal exposed point of the common carotid. PE50 polyeth 
ylene tubing attached to a 30 gauge needle was introduced 
into the internal carotid. Residual blood was rinsed from the 
artery using HEPES buffered saline. The common carotid 
was crushed with hemostats to induce an injury to the 
arterial wall. The artery was then filled with a sterile 5% 
solution of PEG-b-PLL (as described in Example 1) in 
HEPES buffered saline. The Solution remained in the vessel 
for two minutes and then was withdrawn through the tubing. 
The tubing was removed, and the internal carotid was tied 
off with 5-0 silk suture. The arterial clips were then removed 
to allow blood flow. The muscular layer of the incision was 
closed with continuous 3-0 Vicryl suture, and the skin was 
closed with 9 mm staples. Animals were sacrificed at either 
two hours or twenty-four hours post-surgery. The vessels 
were excised, rinsed, and fixed in buffered formalin. At least 
twelve hours later, the vessels were dehydrated in a graded 
ethanol series, exchanged with Xylene, embedded in paraffin, 
sectioned to a thickness of 5 um, and mounted on glass 
slides. Staining was by Masson's trichrome. 
Results 
As expected in the case of an arterial wall injury, all 
control animals displayed significant thrombosis formation, 
both at the two and twenty-four hour time points. Applica 
tion of the PEG-b-PLL solution prevented thrombosis at 
both time points. All treated arteries were completely patent, 
allowing normal blood flow through the carotid artery (at 2 
hour time point, n=2 treatment, n=2 control; at 24 hour time 
point, n=3 treatment, n=2 control; figures shown are typical 
of all n for that condition). 
FIGS. 2a and 2b are photographs at a magnification of 
600 fold of the rat carotid artery 24 hours after crush injury 
without treatment (FIG. 2a) and treated with a 5% solution 
of PEG-b-PLL for two minutes (FIG. 2b). There were no 
signs of adverse tissue response to bi-functional polymer. 
EXAMPLE 5 
Effect of PEG-b-PLL Addition on Tumor Cell 
Seeding In Vivo 
Materials and Methods 
A model of laproscopic surgery was performed. A 16 
gauge angiocatheter was inserted intraperitoneally in male 
C3H mice, and insufflated with 5 ml of air. Three treatments 
were performed, with 18 animals per treatment. Treatment 1 
consisted of the injection of 1x10 tumor cells in one ml of 
phosphate buffered saline. Treatment 2 consisted of injection 













containing 0.1% PLL-b-PEG. Treatment 3 consisted of the 
injection of 1x10 tumor cells in one ml of phosphate 
buffered saline containing 1% PLL-b-PEG. After sixteen 
days, the tumor volume was compared at the trocar site, as 
well as at all other sites. 
Results 
The results are presented in Table 4. Application of 
PLL-b-PEG reduced tumor volume significantly (p<0.05). 
The differences between 0.1% and 1% PLL b PEG were not 
significant. 
TABLE 4 
Tumor Volume at 16 days 
All Other 
Treatment Trocar Site (g) Sites (g) 
control 485 929 
.1% PLL-b-PEG 179 297 
1% PLL-b-PEG 160 173 
EXAMPLE 6 
Synthesis of Methacrylic PEG Copolymerized with 
Aminoethyl Methacrylate 
Monomethoxy PEG was reacted with methacryloyl chlo 
ride under anhydrous conditions, producing methacrylic 
PEG. This was copolymerized with aminoethyl methacry 
late (AEMA), to yield 85AEMA:15 methacrylic PEG. The 
product was then dialyzed against water using the method of 
U.S. Pat. No. 5,075,400 to Andrade, et al. "Polymer super 
surfactants for protein resistance and protein removal'. 
EXAMPLE 7 
Evaluation of AEMA/Methacrylic PEG Copolymer 
In Vitro 
Human foreskin fibroblasts were trypsinized and seeded 
in complete media containing 0.2% (w/v) AEMA/meth 
acrylic PEG copolymer. Cells were seeded on polystyrene 
culture dishes at a concentration of 2000, 15,000, 30,000 
cells/cm. 
TABLE 5 
Concentration of Spread Cells 3 hour 
post-seeding. 
concentration of cells (cells/cm) 
treatent 2000 15,000 30,000 
AEMA copolym. O O O 
Ione 212 >1000 >1000 
The results demonstrate the effectiveness of the polymer 
in preventing attachment and growth of the treated cells, 
especially as compared with the control cells. 
Modifications and variations of the methods and compo 
sitions described herein will be obvious to those skilled in 
the art from the foregoing detailed description. Such modi 
fications and variations are intended to come within the 
scope of the appended claims. 
We claim: 
1. A method for modifying cell contact with a surface, 
comprising applying to the surface a biocompatible poly 
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meric material which is selected from the group consisting 
of copolymers having the formulas (A)xOB)y; (A)x(B- 
)y(A)Z; (B)x(A)y(B)Z; and a brush copolymer (A)x(B)y 
having bristles of poly(A); 
wherein (A)x, (A)y and (A)Z are biocompatible synthetic 
polymers and mixtures of polymers that form a region 
which is polynonionic at a pH of between 6.5 and 8.5 
and does not bind tissue, and 
wherein (B)y, (B)x, and (B)Z are biocompatible, water 
soluble synthetic polymers or mixture of polymers that 
form a region which is polycationic at a pH of between 
6.5 and 8.5 and binds to tissue; and 
wherein x is an integer of greater than or equal to 5, y is 
an integer of greater than or equal to 3, and Z is an 
integer of greater than or equal to 0; 
wherein the polymer has a molecular weight of at least 
300 g/mole. 
2. The method of claim 1 wherein the a biocompatible 
polymeric material is a block copolymer having the formula 
(A)x(B)y. 
3. The method of claim 1 wherein the polymeric material 
further comprises a region C that is subject to degradation in 
vivo by hydrolysis, enzymatic degradation, or oxidation. 
4. The method of claim 1 wherein the tissue binding 
region (B)y converts to a non-tissue binding region when 
exposed to water, oxidation or to enzymatic attack. 
5. The method of claim 1 wherein the non-tissue binding 
region (A)x converts to a tissue binding region when 
exposed to water, oxidation or to enzymatic attack. 
6. The method of claim 1 wherein the polymeric material 
further comprises an agent which is biologically active in a 
patient. 
7. The method of claim 1 wherein the surface is a tissue 
surface, and wherein the polymer is applied to the tissue 
Surface to inhibit tissue adhesion, thrombus formation, res 
tenosis, or metastasis at the surface. 
8. The method of claim 7 wherein the surface is a region 
of a tissue surface that has been surgically cut. 
9. The method of claim 1 wherein the surface is the lining 
of a damaged blood vessel, and wherein the polymer is 
applied to the surface to inhibit thrombosis or adhesion at the 
lining of a blood vessel that has been damaged. 
10. The method of claim 1 wherein the surface is a tissue 
surface, and wherein the polymer is applied to the tissue 
Surface to inhibit attachment of cancerous or tumor cells. 
11. The method of claim 7 wherein the surface is injured 
tissue of an organ or lumen of the body which contacts other 










12. The method of claim 1 wherein the polymer further 
comprises an agent which is biologically active in a patient, 
and wherein the polymer is targeted to attach to specific cell 
types by the agent. 
13. The method of claim 1 wherein the surface is a tissue 
surface that has been chemically fixed or cryopreserved. 
14. The method of claim 1 wherein (A)x and (A)Z are 
selected from the group consisting of poly(oxyalkylene 
oxides), poly(ethyloxazoline), poly(N-vinyl pyrrolidone), 
poly(vinyl alcohol), neutral poly(amino acids) and copoly 
mers of monomers selected from the group consisting of 
oxyalkylene oxides, ethyloxazoline, N-vinyl pyrrollidone, 
vinyl alcohol, and amino acids. 
15. The method of claim 1 wherein (B)y is selected from 
the group consisting of poly(ethyleneimine), quaternary 
amines, and polyamines having amine groups on either the 
polymer backbone or the polymer sidechains. 
16. The method of claim 1 wherein the tissue binding 
region (B)y is formed by polymerization of amides or esters. 
17. The method of claim 1 where the non-tissue binding 
region (A)x is polyanionic and soluble in water. 
18. The method of claim 6 wherein the polymeric material 
is biodegradable, and the biologically active agent is a 
component which is released as the polymer degrades. 
19. The method of claim 6 wherein the biologically active 
agent is chemically coupled to the polymer. 
20. The method of claim 7 wherein the biocompatible 
polymeric material is applied to the tissue surface in com 
bination with a pharmaceutically acceptable carrier. 
21. The method of claim 1 wherein the surface is a tissue 
surface and wherein the application of the polymer to the 
surface inhibits the attachment of cancer cells or platelets to 
the tissue surface. 
22. The method of claim 1 wherein the surface is the 
surface of a tissue at a site of injury to the tissue, and wherein 
the application of the polymer to the surface enhances the 
binding of epithelial cells to the injured site. 
23. The method of claim 1 wherein the surface is selected 
from the group consisting of an injured blood vessel, a 
Surgical anastomosis, an injured serosal Surface, a corneal 
injury and a skin wound. 
24. The method of claim 1 wherein the surface is selected 
from the group consisting of an injured tissue site and an 
implant surface. 
25. The method of claim 1 wherein the Surface is the 
surface of a second cell, and wherein the method comprises 
applying the polymer to the second cell thereby to inhibit or 
enhance contact of the cells. 
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